Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
Pluri (NASDAQ, TASE: PLUR) launched a wholly-owned subsidiary, Cellav Health and Aesthetics, to commercialize exosome-enhanced regenerative skincare using Pluri’s proprietary 3D cell expansion platform.
Pluri announced a commercial collaboration with Miss Universe Skincare to co-develop a line of cell-based skincare products, with the first product expected to launch in the first half of 2026 and be distributed via Miss Universe Skincare’s global platform. The collaboration will be presented during pre-gala activities of the 74th Miss Universe event in Thailand. Management describes the move as part of Pluri’s strategy to enter high-growth, revenue-generating beauty markets.
Pluri (NASDAQ, TASE: PLUR) ha lanciato una sussidiaria interamente controllata, Cellav Health and Aesthetics, per commercializzare la rigenerazione cutanea potenziata da esosomi sfruttando la piattaforma proprietaria 3D di espansione cellulare di Pluri.
Pluri ha annunciato una collaborazione commerciale con Miss Universe Skincare per co-sviluppare una linea di prodotti per la cura della pelle a base di cellule, con il primo prodotto previsto per il lancio nella prima metà del 2026 e sarà distribuito tramite la piattaforma globale di Miss Universe Skincare. La collaborazione sarà presentata durante le attività pre-gala della 74a edizione di Miss Universe in Thailandia. La direzione descrive l'iniziativa come parte della strategia di Pluri per entrare in mercati beauty ad alto tasso di crescita e generazione di ricavi.
Pluri (NASDAQ, TASE: PLUR) lanzó una subsidiaria 100% propiedad, Cellav Health and Aesthetics, para comercializar cuidados regenerativos potenciados con exosomas utilizando la plataforma propietaria de expansión celular 3D de Pluri.
Pluri anunció una colaboración comercial con Miss Universe Skincare para co-desarrollar una línea de productos de cuidado de la piel a base de células, con el primer producto previsto para lanzarse en la primera mitad de 2026 y se distribuirá a través de la plataforma global de Miss Universe Skincare. La colaboración se presentará durante las actividades previas a la gala de la 74.ª edición de Miss Universo en Tailandia. La dirección describe la movida como parte de la estrategia de Pluri para ingresar en mercados de belleza de alto crecimiento y generación de ingresos.
Pluri (나스닥, TASE: PLUR)는 Exosome를 이용한 재생 피부 관리용으로 Pluri의 독점 3D 세포 확장 플랫폼을 활용해 자회사를 100% 보유하는 Cellav Health and Aesthetics를 설립했다.
Pluri는 Miss Universe Skincare와 상업적 협력을 발표하여 세포 기반 피부 관리 제품 라인을 공동 개발하고, 첫 번째 제품은 2026년 상반기에 출시될 예정이며 Miss Universe Skincare의 글로벌 플랫폼을 통해 유통될 것이다. 협력은 태국에서 열리는 제74회 미스 유니버스 행사의 프리 갈라 활동 중에 발표될 것이다. 경영진은 이 움직임을 높은 성장과 매출 창출이 예상되는 뷰티 시장으로 진입하기 위한 Pluri의 전략의 일부로 설명한다.
Pluri (NASDAQ, TASE : PLUR) a lancé une filiale entièrement détenue, Cellav Health and Aesthetics, pour commercialiser des soins regeneratifs améliorés par les exosomes en utilisant la plateforme exclusive d'expansion cellulaire en 3D de Pluri.
Pluri a annoncé une collaboration commerciale avec Miss Universe Skincare pour co-développer une ligne de soins basés sur des cellules, le premier produit devant être lancé dans la première moitié de 2026 et sera distribué via la plateforme mondiale de Miss Universe Skincare. La collaboration sera présentée lors des activités pré-gala du 74e édition de Miss Universe en Thaïlande. La direction décrit cette initiative comme faisant partie de la stratégie de Pluri pour entrer sur des marchés de beauté à forte croissance et génératrices de revenus.
Pluri (NASDAQ, TASE: PLUR) hat eine hundertprozentige Tochtergesellschaft, Cellav Health and Aesthetics, gegründet, um exosome-verbesserte regenerative Hautpflege mithilfe von Pluris eigener 3D-Zellexpansion-Plattform zu kommerzialisieren.
Pluri kündigte eine kommerzielle Zusammenarbeit mit Miss Universe Skincare an, um gemeinsam eine Linie zellbasierter Hautpflegeprodukte zu entwickeln; das erste Produkt soll in der ersten Hälfte 2026 auf den Markt kommen und über die globale Plattform von Miss Universe Skincare vertrieben werden. Die Zusammenarbeit wird während der Vor-Gala-Aktivitäten der 74. Miss-Universum-Veranstaltung in Thailand vorgestellt. Das Management beschreibt den Schritt als Teil von Pluris Strategie, in wachstumsstarke, umsatzgenerierende Schönheitsmärkte einzutreten.
Pluri (المدرجة في Nasdaq وتاسي: PLUR) أطلقت شركة فرعية مملوكة بالكامل، Cellav Health and Aesthetics، لتسويق العناية بالبشرة التجديدية المعززة بالزيجوسومات باستخدام منصة التوسع الخلوي ثلاثية الأبعاد المملوكة لـ Pluri.
أعلنت Pluri عن تعاون تجاري مع Miss Universe Skincare لتطوير خط من منتجات العناية بالبشرة القائمة على الخلايا بشكل مشترك، مع توقع إطلاق أول منتج في النصف الأول من عام 2026 وسيتم توزيعه عبر منصة Miss Universe Skincare العالمية. سيتم عرض التعاون خلال فعاليات ما قبل الحفل للحدث 74miss Universe في تايلاند. تصف الإدارة هذه الخطوة كجزء من استراتيجيتها لدخول أسواق التجميل عالية النمو وتوليد الإيرادات.
- Cellav subsidiary launched on Nov 11, 2025
- First product expected H1 2026 for global distribution
- Commercial collaboration secured with Miss Universe Skincare for global channel
- None.
Insights
Pluri launches Cellav and a global Miss Universe Skincare collaboration to commercialize exosome-based beauty products, first launch expected in
Pluri created a wholly-owned subsidiary, Cellav, to commercialize exosome-based actives produced on Pluri’s proprietary 3D cell expansion platform. The business model pairs a technology-origin company with a global consumer brand, using Cellav to supply a proprietary cell-based active for a co-developed skincare line distributed via Miss Universe Skincare’s global platform.
Key dependencies and risks are explicit: product safety, regulatory clearance for cell-derived exosome actives in consumer skincare, and successful scale-up of manufacturing under the stated quality standards. The announcement limits claims to intended benefits (rejuvenation, elasticity, radiance) and sets a near-term commercialization milestone rather than clinical outcomes.
Concrete items to watch: the actual product launch in
- Pluri launches wholly-owned health and aesthetics subsidiary Cellav- leveraging Pluri’s proprietary 3D cell expansion platform to deliver advanced exosome-based technologies for medical aesthetics
- The partnership with Miss Universe Skincare, a global beauty and wellness entity, establishes a global distribution channel in the beauty market, which is projected to reach
$194.05 billion by 2032
HAIFA, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the launch of Cellav Health and Aesthetics Ltd. (“Cellav”), its wholly-owned health and aesthetics subsidiary, focused on developing science-driven and regenerative solutions powered by Pluri’s proprietary 3D cell expansion platform. The launch follows Cellav’s first secured commercial collaboration with Miss Universe Skincare (“Miss Universe Skincare”), a global skincare and beauty brand. The collaboration will focus on the co-development of a new line of advanced, cell-based skincare products.
Cellav is expected to supply a proprietary cell-based active ingredient, developed using Pluri’s cell expansion platform, for use in a new series of skincare products expected to be launched under the Miss Universe Skincare label. The first product is expected to launch during the first half of 2026 and will be distributed through Miss Universe Skincare’s global platform. The official presentation of this collaboration is expected to take place during the pre-gala activities of the 74th Miss Universe event in Thailand. This collaboration marks a major milestone in Pluri’s strategy to expand into high-growth, revenue-generating markets. Cellav’s solutions combine regenerative biotechnology with the global appeal of beauty and wellness to meet rising consumer demand for credible, science-based skincare. Derived from various cell sources and manufactured under the highest quality standards, Cellav’s exosomes are designed to enhance skin rejuvenation, elasticity, and radiance.
“At Miss Universe Skincare, we believe that true beauty begins at the cellular level,” said Olivia Quido, President of Miss Universe Skincare and Vice President of Global Partnerships, Miss Universe Organization. “Through our collaboration with Cellav by Pluri, we are proud to introduce the extraordinary benefits of exosome technology - one of the most advanced frontiers in skincare science. Exosomes derived from regenerative biotechnology help boost skin rejuvenation, enhance elasticity, and restore natural luminosity. By integrating these powerful actives into our formulations, we continue our mission to empower every individual to glow with confidence, vitality, and purpose.”
Cellav is led by Chief Executive Officer Katty Dowery, a pharmaceutical engineer and biotechnology executive with over a decade of experience in cell-based technologies, regenerative medicine, and product innovation. As a long-time leader within Pluri, she brings a strong track record of translating advanced science into commercial success.
“At Cellav, we’re bridging advanced biotechnology with the world of beauty,” said Ms. Dowery. “Through my work with cells and regenerative medicine, I’ve seen the remarkable potential of this science. I believe it shouldn’t remain confined to laboratories or clinical research - it should enhance how we look, feel, and live every day. Our mission is to make regenerative science accessible and impactful. What sets us apart is our scientific integrity, deep cell-based technology expertise, and commitment to the highest quality standards. We believe the future of beauty lies in regenerative biotechnology, and with Pluri’s platform behind us, we’re ready to lead the way.”
“Our partnership with Miss Universe Skincare marks more than just a strategic brand collaboration- it’s a clear step forward in Pluri’s focused strategy to apply our platform where we believe our technology can make the greatest impact,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “By launching Cellav, we are expanding into a high-demand market with a differentiated, science-driven offering—one that aligns with our commitment to near-term revenue generation, scalable innovation, and advancing global wellbeing.”
About Cellav
Cellav is Pluri’s subsidiary, dedicated to transforming cutting-edge cell science into high-impact solutions for health and aesthetics. At its core, Cellav is built to bridge science and real-world results-delivering flexible, business-to-business offerings that meet the growing demand for regenerative, credible, and customizable beauty innovations. Cellav plans to operate through three core areas: (i) Cellav develops premium cell-derived ingredients- such as exosomes and cell extracts—that can be integrated into partner formulations or devices; (ii) Cellav offers professional-use and consumer-ready skincare and haircare products powered by regenerative actives; and (iii) Cellav provides a flexible technology platform that enables partners to scale production, co-develop innovative solutions, and launch white-label or co-branded products. Cellav intends to work with global beauty brands, device manufacturers, medical clinics, and distributors. Its business model is intentionally adaptable, supporting licensing, joint ventures, and royalty-based collaborations. All offerings are backed by over two decades of Pluri’s expertise, rooted in pharmaceutical-grade development and designed to scale with partners around the world. Learn more at visit: https://pluri-biotech.com/revolutionizing-the-beauty-industry/
About Miss Universe Skincare
Miss Universe Skincare, the official skincare line inspired by the Miss Universe brand, combines science and luxury to empower individuals to glow with confidence and purpose. Each formula features the proprietary MU7C+ Complex, a blend of age-defying actives sourced from seven continents, and innovative drone-delivery technology designed to optimize efficacy and achieve luminous, even-toned skin. Founded and led by Olivia Quido, President of Miss Universe Skincare and Vice President of Global Partnerships, Miss Universe Organization, Miss Universe Skincare reflects a legacy of excellence, global reach, and professional trust. Its products have been selected as the official skincare regimen used by Miss Universe contestants worldwide. Together with Cellav by Pluri, Miss Universe Skincare continues to elevate the standards of modern skincare through innovation, integrity, and results-driven beauty science. To learn more, visit http://www.missuniverseskincare.com
About Pluri
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, aesthetics and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Cellav’s platform and development capabilities, dedication and ability to deliver solutions and technologies for medical aesthetics, including by leveraging Pluri’ platforms; projections of the beauty markets; the development of a new line of skincare products as part of the collaboration and the expected timeline and location of the first product launch; Cellav’s ability to supply the ingredients under the agreement; Pluri’s ability to expand into high-growth and revenue-generating verticals; the exosomes’ abilities; the expectations from Cellav’s Chief Executive Officer; Cellav’s products’ ability to deliver measurable results; the potential impact of Pluri’s technology; the expectation that Pluri will expand into a high-demand market; the expectation of revenue-generation; and Pluri’s continued ability to accelerate breakthroughs that address global challenges. These forward-looking statements and their implications are based on the current expectations of Pluri and Cellav’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the collaboration may not be realized as anticipated; Pluri may encounter changes in technology or market conditions; Pluri and Cellav may face challenges in launching or scaling new products and product lines; regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; and intensified competition in the medical aesthetics and wellness space. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
FAQ
What did Pluri announce about Cellav on November 11, 2025 (PLUR)?
When is PLUR’s first Cellav product expected to launch and where will it be sold?
What is the scope of Pluri’s collaboration with Miss Universe Skincare (PLUR)?
Will Pluri present the Cellav collaboration at Miss Universe events (PLUR)?
How does Pluri describe the strategic purpose of launching Cellav (PLUR)?
